默克-话题@MedSci

#默克#

100篇内容 | 3148人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1273929, encodeId=a63812e392964, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克Keytruda存在的重要安全问题和美国临床处理办法, objectType=article, longId=184099, objectId=21e5184099cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21e5184099cb, replyNumber=0, likeNumber=59, createdTime=2019-12-05, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21e5184099cb, moduleTitle=默克Keytruda存在的重要安全问题和美国临床处理办法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21e5184099cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273928, encodeId=f2b212e39283d, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克PD-1单抗KEYTRUDA（pembrolizumab）目前在美国获批的所有适应症：14种癌症的治疗, objectType=article, longId=184092, objectId=92cd1840921e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92cd1840921e, replyNumber=0, likeNumber=62, createdTime=2019-12-05, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92cd1840921e, moduleTitle=默克PD-1单抗KEYTRUDA（pembrolizumab）目前在美国获批的所有适应症：14种癌症的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92cd1840921e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273927, encodeId=1f2a12e392731, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克的PD-1单抗Keytruda获得国内非小细胞肺癌适应症的第三次批准, objectType=article, longId=184025, objectId=7f2c18402514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f2c18402514, replyNumber=0, likeNumber=67, createdTime=2019-12-04, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f2c18402514, moduleTitle=默克的PD-1单抗Keytruda获得国内非小细胞肺癌适应症的第三次批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f2c18402514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273926, encodeId=e6d812e39266e, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克的PD-1单抗Keytruda大大延长了部分晚期前列腺癌患者的生存期, objectType=article, longId=184023, objectId=8e3e1840235e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e3e1840235e, replyNumber=0, likeNumber=78, createdTime=2019-12-04, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e3e1840235e, moduleTitle=默克的PD-1单抗Keytruda大大延长了部分晚期前列腺癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e3e1840235e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273925, encodeId=0a5512e392567, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=美国临床医生最喜欢哪款多发性硬化症药物？诺华、默克还是Biogen的？, objectType=article, longId=183458, objectId=aa7d1834581c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa7d1834581c, replyNumber=0, likeNumber=80, createdTime=2019-11-24, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa7d1834581c, moduleTitle=美国临床医生最喜欢哪款多发性硬化症药物？诺华、默克还是Biogen的？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa7d1834581c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273924, encodeId=9dcb12e392400, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克（Merck）首席财务官强调：我们不仅有Keytruda, objectType=article, longId=182340, objectId=e72b182340f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e72b182340f8, replyNumber=0, likeNumber=53, createdTime=2019-11-05, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e72b182340f8, moduleTitle=默克（Merck）首席财务官强调：我们不仅有Keytruda, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e72b182340f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273923, encodeId=f43212e392322, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=全新预测2025年默克keytruda销售额排名将直冲**，达225亿美元，Humira则降至第六, objectType=article, longId=180595, objectId=d8b218059519, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8b218059519, replyNumber=0, likeNumber=60, createdTime=2019-10-08, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8b218059519, moduleTitle=全新预测2025年默克keytruda销售额排名将直冲**，达225亿美元，Humira则降至第六, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8b218059519)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273922, encodeId=837712e392203, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗, objectType=article, longId=180183, objectId=e8d718018362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8d718018362, replyNumber=0, likeNumber=75, createdTime=2019-09-29, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8d718018362, moduleTitle=NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8d718018362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273921, encodeId=89e712e392140, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克的埃博拉疫苗V920获得了FDA的优先审查, objectType=article, longId=179676, objectId=a3701e9676a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3701e9676a0, replyNumber=0, likeNumber=57, createdTime=2019-09-20, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3701e9676a0, moduleTitle=默克的埃博拉疫苗V920获得了FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3701e9676a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273920, encodeId=a7de12e3920ae, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=FDA警告：与AbbVie、默克、吉利德的丙型肝炎药物有关的罕见严重肝损伤病例, objectType=article, longId=178359, objectId=35221e8359a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=35221e8359a2, replyNumber=0, likeNumber=49, createdTime=2019-08-31, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=35221e8359a2, moduleTitle=FDA警告：与AbbVie、默克、吉利德的丙型肝炎药物有关的罕见严重肝损伤病例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=35221e8359a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273919, encodeId=d22812e3919d3, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克将以7.77亿美元收购Tilos，增加其免疫治疗管线, objectType=article, longId=168069, objectId=3a4f1680693d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a4f1680693d, replyNumber=0, likeNumber=52, createdTime=2019-06-12, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a4f1680693d, moduleTitle=默克将以7.77亿美元收购Tilos，增加其免疫治疗管线, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a4f1680693d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273918, encodeId=e70c12e391815, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克加速器开启新一轮申请, objectType=article, longId=167792, objectId=405316e792ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=405316e792ce, replyNumber=0, likeNumber=50, createdTime=2019-06-08, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=405316e792ce, moduleTitle=默克加速器开启新一轮申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=405316e792ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273917, encodeId=1fb812e3917d8, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=在创新中推动发展，六家初创企业正式入驻默克中国创新加速器, objectType=article, longId=167684, objectId=6cf216e684c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cf216e684c9, replyNumber=0, likeNumber=82, createdTime=2019-06-06, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cf216e684c9, moduleTitle=在创新中推动发展，六家初创企业正式入驻默克中国创新加速器, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cf216e684c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273916, encodeId=3e6f12e391614, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=2019 ASCO：诺华和默克治疗MET突变非小细胞肺癌的候选药，在2期临床均显示出治疗活性, objectType=article, longId=167679, objectId=019216e679c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=019216e679c8, replyNumber=0, likeNumber=68, createdTime=2019-06-06, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=019216e679c8, moduleTitle=2019 ASCO：诺华和默克治疗MET突变非小细胞肺癌的候选药，在2期临床均显示出治疗活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=019216e679c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273915, encodeId=d39812e39159b, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=FDA批准默克的PD-L1单抗联合阿西替尼，用于治疗晚期肾细胞癌, objectType=article, longId=166173, objectId=9b091661e313, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b091661e313, replyNumber=0, likeNumber=72, createdTime=2019-05-17, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b091661e313, moduleTitle=FDA批准默克的PD-L1单抗联合阿西替尼，用于治疗晚期肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b091661e313)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273914, encodeId=26a512e3914ce, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=浙江大学加入默克CRISPR核心合作伙伴，持续发力基因编辑技术, objectType=article, longId=162735, objectId=772e162e3583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=772e162e3583, replyNumber=0, likeNumber=61, createdTime=2019-03-23, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=772e162e3583, moduleTitle=浙江大学加入默克CRISPR核心合作伙伴，持续发力基因编辑技术, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=772e162e3583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273913, encodeId=459b12e391328, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克将与金斯瑞一起帮助加速中国细胞和基因治疗产业化, objectType=article, longId=162668, objectId=438d16266843, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=438d16266843, replyNumber=0, likeNumber=60, createdTime=2019-03-22, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=438d16266843, moduleTitle=默克将与金斯瑞一起帮助加速中国细胞和基因治疗产业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=438d16266843)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273912, encodeId=974112e3912ac, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=浙江大学与默克建立CRISPR合作关系, objectType=article, longId=162518, objectId=ddb916251841, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ddb916251841, replyNumber=0, likeNumber=51, createdTime=2019-03-19, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddb916251841, moduleTitle=浙江大学与默克建立CRISPR合作关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddb916251841)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273911, encodeId=467d12e391131, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效, objectType=article, longId=161940, objectId=45871619401a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45871619401a, replyNumber=0, likeNumber=56, createdTime=2019-03-10, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45871619401a, moduleTitle=欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45871619401a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273910, encodeId=7c0c12e391005, content=<a href='/topic/show?id=4909103353c5' target=_blank style='color:#2F92EE;'>#默克#</a>, objectTitle=默克Keytruda治疗晚期肝癌的III期临床试验失败告终, objectType=article, longId=160650, objectId=909e1606500c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=909e1606500c, replyNumber=0, likeNumber=86, createdTime=2019-02-22, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=909e1606500c, moduleTitle=默克Keytruda治疗晚期肝癌的III期临床试验失败告终, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=909e1606500c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

默克

2020-05-29

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克Keytruda存在的重要安全问题和美国临床处理办法

2019-12-05

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克PD-1单抗KEYTRUDA（pembrolizumab）目前在美国获批的所有适应症：14种癌症的治疗

2019-12-05

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克的PD-1单抗Keytruda获得国内非小细胞肺癌适应症的第三次批准

2019-12-04

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克的PD-1单抗Keytruda大大延长了部分晚期前列腺癌患者的生存期

2019-12-04

makuansheng (审核中...)

前往app查看评论内容

#默克#

美国临床医生最喜欢哪款多发性硬化症药物？诺华、默克还是Biogen的？

2019-11-24

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克（Merck）首席财务官强调：我们不仅有Keytruda

2019-11-05

makuansheng (审核中...)

前往app查看评论内容

#默克#

全新预测2025年默克keytruda销售额排名将直冲**，达225亿美元，Humira则降至第六

2019-10-08

makuansheng (审核中...)

前往app查看评论内容

#默克#

NMPA批准默克的EGFR单抗西妥昔联合FOLFOX或FOLFIRI化疗，用于国内RAS野生型转移性结直肠癌患者的一线治疗

2019-09-29

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克的埃博拉疫苗V920获得了FDA的优先审查

2019-09-20

makuansheng (审核中...)

前往app查看评论内容

#默克#

FDA警告：与AbbVie、默克、吉利德的丙型肝炎药物有关的罕见严重肝损伤病例

2019-08-31

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克将以7.77亿美元收购Tilos，增加其免疫治疗管线

2019-06-12

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克加速器开启新一轮申请

2019-06-08

makuansheng (审核中...)

前往app查看评论内容

#默克#

在创新中推动发展，六家初创企业正式入驻默克中国创新加速器

2019-06-06

makuansheng (审核中...)

前往app查看评论内容

#默克#

2019 ASCO：诺华和默克治疗MET突变非小细胞肺癌的候选药，在2期临床均显示出治疗活性

2019-06-06

makuansheng (审核中...)

前往app查看评论内容

#默克#

FDA批准默克的PD-L1单抗联合阿西替尼，用于治疗晚期肾细胞癌

2019-05-17

makuansheng (审核中...)

前往app查看评论内容

#默克#

浙江大学加入默克CRISPR核心合作伙伴，持续发力基因编辑技术

2019-03-23

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克将与金斯瑞一起帮助加速中国细胞和基因治疗产业化

2019-03-22

makuansheng (审核中...)

前往app查看评论内容

#默克#

浙江大学与默克建立CRISPR合作关系

2019-03-19

makuansheng (审核中...)

前往app查看评论内容

#默克#

欧洲药品管理局验证了默克PD-L1单抗Bavencio在晚期肾细胞癌中的疗效

2019-03-10

makuansheng (审核中...)

前往app查看评论内容

#默克#

默克Keytruda治疗晚期肝癌的III期临床试验失败告终

2019-02-22

科室
- - 订阅+
  - 更多科室
工具
服务